Ernest Pharmaceuticals seeks to create a novel bacterial platform that revolutionizes cancer treatment success through innovations in intracellular macromolecule delivery.
Therapeutic bacteria have unique properties that enable them to treat metastatic disease and inoperable tumors. These organisms are motile and actively penetrate into tumor tissue.
Ernest Pharmaceuticals’ focus is on tumors with low survival rates, such as liver, pancreas, ovarian and metastatic breast cancer. For these patients, very few therapeutic possibilities exist that greatly improve overall survival time. Bacterial cancer therapies have the potential to change these high mortality rates.